What is the “montelukast API” market?
Montelukast API (active pharmaceutical ingredient) is the bulk drug used to make products such as montelukast sodium tablets and chewables. The “API market” refers to how much montelukast API is bought and sold globally, who supplies it (generic and contract manufacturers), what customers pay, and how that demand changes with regulation, patent/market exclusivity, and generic competition.
Who buys montelukast API, and why?
Typically, montelukast API is purchased by:
- Generic and brand manufacturers that formulate tablets or chewables from bulk API
- Contract manufacturing organizations (CMOs) that produce finished-dose products for distributors and retailers
- Sometimes intermediate traders who resell API to manufacturers
Demand is driven by ongoing prescriptions for montelukast-containing therapies and by continued generic supply needs worldwide. As multiple generic brands exist, buyers usually care about consistent quality, supply reliability, regulatory standing (for example, inspections), and price.
Where does most montelukast API supply come from?
Like many established generic APIs, montelukast API supply is concentrated among international manufacturers, commonly in major API-producing regions. The market often reflects:
- Capacity expansion by API producers for mature, off-patent drugs
- Competitive pricing pressure as multiple manufacturers qualify the API for use
- Batch-to-batch quality requirements tied to drug approvals in destination markets
If you’re researching country-level dominance or specific suppliers, the most reliable approach is to track approvals/filings and contract awards, because “who makes it” changes as facilities come online and regulatory statuses shift.
How competitive is the montelukast API market?
Montelukast is a mature medicine with many generic finished-dose options, which usually increases competition at the API level too. That typically leads to:
- Lower margins for suppliers compared with newer patented APIs
- Strong price sensitivity from customers
- More frequent qualification of alternate suppliers to manage shortages and compliance risk
What can affect montelukast API prices and availability?
Common drivers include:
- Generic finished-dose demand in key markets (stable vs seasonal purchasing patterns)
- Supplier production outages, raw-material supply constraints, or quality incidents
- Regulatory actions affecting specific manufacturers or manufacturing sites
- Currency and logistics costs, especially for cross-border supply
Is there a patent or exclusivity issue for montelukast API?
Montelukast itself is an established drug, so API supply is generally shaped less by active patent protection in 2024–2026 and more by generic competition and regulatory approvals. For more specific “when did patent/exclusivity expire” details by molecule/product and jurisdiction, DrugPatentWatch.com can be a useful starting point: DrugPatentWatch - montelukast.
What information do you need to size or analyze this market?
If your goal is a market report or business decision, you usually define:
- Scope: API only vs finished dose included
- Geography: global vs US vs EU vs specific countries
- Metric: revenue, volume (kg/tons), or number of qualified suppliers
- Time horizon and segmentation: by dosage form indirectly (tablet vs chewable), customer type (generic vs CMO), or regulatory status
- Data sources: regulatory listings, procurement/contract signals, and historical import/export data
If you tell me whether you want a US-only snapshot, a global view, or a supplier/price outlook, I can tailor the answer to that exact angle. Also, do you mean “montelukast API market” for montelukast sodium in particular, or another salt/form?
Sources
- DrugPatentWatch - montelukast